Search
for

    Sort by

    Research 481–510 of 1000+

    1. 861 EGFR/MEK inhibitor therapy induces partial hair follicle immune privilege collapse in vivo and ex vivo Journal of Investigative Dermatology · 2022
    2. Olumiant® (Baricitinib)-A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata. PubMed · 2022
    3. 318 The Wnt-inhibitor Dkk4 is required for primary hair follicle induction and patterning Journal of Investigative Dermatology · 2021
    4. 5-Alpha-Reductase Inhibitor Treatment for Frontal Fibrosing Alopecia:A Myth or Truth? Clinical research in dermatology · 2021
    5. VIBRATIONAL SPECTROSCOPIC INVESTIGATION AND MOLECULAR STRUCTURE OF A 5α-REDUCTASE INHIBITOR: FINASTERIDE Figshare · 2021
    6. 705 Influence of 5a-Reductase Inhibitor (5-ARI) Usage on the Reproductive Function of Married Men The Journal of Sexual Medicine · 2018
    7. MP85-05 SEXUAL DYSFUNCTION AFTER 5-ALPHA REDUCTASE INHIBITOR USE: INSIGHTS FROM THE REDUCE STUDY GROUP DATABASE The Journal of Urology · 2018
    8. 307 Dermatologic toxicities associated with chronic gamma-secretase inhibitor treatment for desmoid tumor 2017
    9. FDA approves label addition for PDE-5 inhibitor Urology Times eNews · 2013
    10. Re: Effect of Testosterone Supplementation With and Without a Dual 5α-Reductase Inhibitor on Fat-Free Mass in Men with Suppressed Testosterone Production: A Randomized Controlled Trial The Journal of Urology · 2012
    11. - Tumor necrosis factor-alpha inhibitor associated psoriasiform alopecia (drug-induced psoriasiform alopecia) CRC Press eBooks · 2012
    12. Tumor necrosis factor-alpha inhibitor associated psoriasiform alopecia (drug-induced psoriasiform alopecia) Informa Healthcare eBooks · 2012
    13. ChemInform Abstract: Discovery of a Novel Hybrid from Finasteride and Epristeride as 5α‐Reductase Inhibitor. ChemInform · 2011
    14. 5α-Reductase inhibitor therapy: Should physicians be concerned with persistent diminished libido, erectile dysfunction and depression in a subset of patients? Journal of Men's Health · 2010
    15. Metabolite identification by mass spectrometry of the 5α-reductase inhibitor finasteride in vitro and in vivo 2009
    16. Effects of lipid and acne inhibitive cream on acne model of rabbit's ears Journal of Zhengzhou University · 2009
    17. Synthesis of 5α-Reductase Special inhibitor Finasteride Journal of Xingtai University · 2009
    18. A New Look at the 5á-Reductase Inhibitor Finasteride 2006
    19. マストミス雌雄前立腺における5α-reductase inhibitor (Finasteride)の影響 2006
    20. RE: EFFECT OF THE DUAL 5α-REDUCTASE INHIBITOR DUTASTERIDE ON MARKERS OF TUMOR REGRESSION IN PROSTATE CANCER 2005
    21. Solubilization and Solid‐State Characterization of a Poorly Soluble 5‐α Reductase Inhibitor Drug Development and Industrial Pharmacy · 2004
    22. The 5α-reductase inhibitor finasteride reduces opioid self-administration bioRxiv (Cold Spring Harbor Laboratory) · 2020
    23. VIBRATIONAL SPECTROSCOPIC INVESTIGATION AND MOLECULAR STRUCTURE OF A 5α-REDUCTASE INHIBITOR: FINASTERIDE Química Nova · 2020
    24. Effects of 5-?±-Reductase Inhibitor (Finasteride) on Per Operative Blood Loss in Patients with BPH undergoing TURP International Journal of Medical Research and Health Sciences · 2018
    25. A quantitative hair growth assessment in female androgenetic alopecia during one year, and its modulation by a topical 5?-reductase inhibitor Journal of The European Academy of Dermatology and Venereology · 1998
    26. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata JCI insight · 2016 · 222 citations
    27. The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: Results of a randomized placebo-controlled study of dutasteride versus finasteride Journal of The American Academy of Dermatology · 2006 · 215 citations
    28. APCDD1 is a novel Wnt inhibitor mutated in hereditary hypotrichosis simplex Nature · 2010 · 199 citations
    29. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma ˜The œoncologist · 2016 · 127 citations
    30. Cystatin M/E Is a High Affinity Inhibitor of Cathepsin V and Cathepsin L by a Reactive Site That Is Distinct from the Legumain-binding Site 2006 · 100 citations